APIS Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
The APIS study is testing a blood-thinning tablet called apixaban (also known as Eliquis) in adults with a liver condition called intrahepatic non-cirrhotic portal hypertension. In this condition, blood pressure inside the veins connected to the liver is higher than normal, even though the liver does not have severe scarring (cirrhosis). This high pressure puts people at risk of developing blood clots in their liver veins, which can cause serious complications. Researchers want to see if taking a low dose of apixaban twice a day can safely stop these blood clots from forming or getting worse. This is a Phase 3 study, meaning apixaban is being compared against a dummy pill (placebo) to confirm how well it works. Participants will be monitored closely for two years with regular check-ups, blood tests, and CT scans to look closely at their liver veins.
At a glance
What is this study about?
Blood flows from your digestive organs to your liver through a network of vessels called the portal vein system. In some people, blood pressure inside these vessels becomes unusually high, even though their liver is not damaged by cirrhosis (severe scarring). This condition is called intrahepatic non-cirrhotic portal hypertension. A major danger of this condition is that blood clots can easily form inside these high-pressure veins, blocking normal blood flow and causing pain or further liver problems.
Doctors often use blood-thinning medicines to prevent clots in other conditions, but they need to know if this approach is safe and effective for people with this specific liver problem. This clinical trial tests a well-known blood thinner called apixaban (Eliquis). Participants are split by chance into two groups: one group takes apixaban tablets, and the other takes matching dummy tablets, known as a placebo.
Over a period of two years, doctors will use CT scans (detailed X-ray pictures of the inside of the body) to check whether blood clots form or grow. By comparing the two groups, researchers hope to find out if apixaban provides reliable protection against blood clots without causing harmful bleeding, helping to guide better treatment for patients across the UK and beyond.
Key takeaways
- The APIS trial tests if apixaban can safely prevent blood clots in the veins of the liver.
- It is designed for adults aged 18 and older with non-cirrhotic portal hypertension.
- Participants will take either apixaban tablets or a dummy pill (placebo) for two years.
- Regular CT scans and hospital visits are used to monitor the liver veins closely.
- Joining is entirely voluntary, and you can withdraw at any point without losing your regular care.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with intrahepatic non-cirrhotic portal hypertension. Both men and women are eligible to take part.
Because apixaban is a medicine that thins the blood, doctors must make sure it is safe for each person. People who have an unusually high risk of bleeding, who have recently had severe bleeding, or who already take certain other blood-thinning medicines may not be able to join.
Your hospital specialist will review your full medical history, blood results, and previous liver scans to confirm whether this study is safe and suitable for your specific circumstances.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with non-cirrhotic portal hypertension (high pressure in the liver veins without cirrhosis).
- I do not currently have a known active bleeding condition.
- I am willing and able to take study tablets every day for up to two years.
- I am able to attend regular hospital appointments and have CT scans.
What does participation involve?
Taking part in this study lasts for up to two years (24 months). If you agree to take part, you will be randomly assigned to take either apixaban (2.5 mg) or a matching dummy pill (placebo) as a tablet. Neither you nor your doctor will choose which pill you receive.
You will attend planned appointments at your hospital clinic throughout the two years. During these visits, the study team will ask how you are feeling, check your vital signs, and take routine blood tests. You will also have scheduled CT scans so the team can look closely at the veins around your liver to check for any signs of blood clots. You will be given clear instructions on how to take your tablets and what to do if you feel unwell at any time.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a placebo and why is it used?
A placebo is a dummy pill that looks just like the real medicine but contains no active drug. It helps researchers prove whether any improvements are truly caused by apixaban rather than chance.
Will I know if I am taking apixaban or the placebo?
No. This is a 'blinded' trial, meaning neither you nor your study doctor will know which tablet you are taking. However, if there is an emergency, the doctors can quickly find out.
What are the common side effects of apixaban?
Because apixaban thins the blood, the most common side effects are mild bleeding, such as nosebleeds, bleeding gums when brushing teeth, or bruising more easily than usual.
Can I stop taking part if I change my mind?
Yes. You have the right to leave the study at any time, for any reason. Deciding to leave will not affect your standard NHS treatment or your relationship with your medical team.
Will taking part cost me anything?
No, the study medication and extra scans are provided free of charge. Many trials also offer help to cover reasonable travel expenses for hospital visits.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.